Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Primary Purpose
Onychomycosis
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Efinaconazole
Sponsored by
About this trial
This is an interventional treatment trial for Onychomycosis
Eligibility Criteria
Key Inclusion Criteria:
- Male or female subjects of any race, 6 to 16 years of age (inclusive). PK Subset: Male or female subjects of any race, 12 to 16 years of age (inclusive).
- Verbal and written informed consent/assent obtained from the subject and/or their parent or legal guardian.
- Good general health, as assessed by the investigator, based on the subject's medical history, physical examination, and safety laboratory tests.
- Target great toenail for all subjects, and both great toenails for subjects in the PK subset, must have evidence of toenail growth, per subject's report that monthly clipping is needed.
- Subjects and their parents/legal guardians are willing to comply with study instructions and return to the investigational center for all required visits (a visit schedule with the length of each visit will be provided to ensure that the subject can meet the requirements and have adequate transportation).
Key Exclusion Criteria:
- Females who are pregnant, nursing an infant, or planning a pregnancy during the study period.
- History of immunosuppression and/or clinical signs indicative of possible immunosuppression, as determined by the investigator, or known human immunodeficiency virus infection.
- History of diabetes that is uncontrolled as determined by the investigator (diabetes that is controlled by diet or medication does not exclude a subject).
- Presence of any toenail infection other than or in addition to dermatophytes, such as Scytalidium as determined by the investigator (candidal onychomycosis infection, concurrent with a positive dermatophyte culture, is acceptable).
Sites / Locations
- Valeant Site 01
- Valeant Site 04
- Valeant Site 03
- Valeant SIte 05
- Valeant Site 09
- Valeant Site 08
- Valeant Site 02
- Valeant Site 06
- Valeant Site 07
- Valeant Site 10
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Efinaconazole
Arm Description
Efinaconazole
Outcomes
Primary Outcome Measures
Percentage of Participants With at Least One Adverse Event
Secondary Outcome Measures
Full Information
NCT ID
NCT02812771
First Posted
June 22, 2016
Last Updated
October 1, 2021
Sponsor
Bausch Health Americas, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02812771
Brief Title
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Official Title
A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
August 4, 2016 (Actual)
Primary Completion Date
January 14, 2019 (Actual)
Study Completion Date
January 14, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bausch Health Americas, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
Detailed Description
This is an open label, single-arm study designed to evaluate the safety and PK of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Onychomycosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Efinaconazole
Arm Type
Experimental
Arm Description
Efinaconazole
Intervention Type
Drug
Intervention Name(s)
Efinaconazole
Intervention Description
Solution
Primary Outcome Measure Information:
Title
Percentage of Participants With at Least One Adverse Event
Time Frame
48 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Key Inclusion Criteria:
Male or female subjects of any race, 6 to 16 years of age (inclusive). PK Subset: Male or female subjects of any race, 12 to 16 years of age (inclusive).
Verbal and written informed consent/assent obtained from the subject and/or their parent or legal guardian.
Good general health, as assessed by the investigator, based on the subject's medical history, physical examination, and safety laboratory tests.
Target great toenail for all subjects, and both great toenails for subjects in the PK subset, must have evidence of toenail growth, per subject's report that monthly clipping is needed.
Subjects and their parents/legal guardians are willing to comply with study instructions and return to the investigational center for all required visits (a visit schedule with the length of each visit will be provided to ensure that the subject can meet the requirements and have adequate transportation).
Key Exclusion Criteria:
Females who are pregnant, nursing an infant, or planning a pregnancy during the study period.
History of immunosuppression and/or clinical signs indicative of possible immunosuppression, as determined by the investigator, or known human immunodeficiency virus infection.
History of diabetes that is uncontrolled as determined by the investigator (diabetes that is controlled by diet or medication does not exclude a subject).
Presence of any toenail infection other than or in addition to dermatophytes, such as Scytalidium as determined by the investigator (candidal onychomycosis infection, concurrent with a positive dermatophyte culture, is acceptable).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Binu Alexander, MD
Organizational Affiliation
Valeant Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Valeant Site 01
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35201
Country
United States
Facility Name
Valeant Site 04
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
Valeant Site 03
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95403
Country
United States
Facility Name
Valeant SIte 05
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
Valeant Site 09
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70130
Country
United States
Facility Name
Valeant Site 08
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21214
Country
United States
Facility Name
Valeant Site 02
City
Forest Hills
State/Province
New York
ZIP/Postal Code
11375
Country
United States
Facility Name
Valeant Site 06
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Valeant Site 07
City
McAllen
State/Province
Texas
ZIP/Postal Code
78501
Country
United States
Facility Name
Valeant Site 10
City
Santo Domingo
Country
Dominican Republic
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
We'll reach out to this number within 24 hrs